 ANGLE plc  Annu Al Repo Rt And Accounts 2007  Operational highlights
Significant  further  investment  into  existing  portfolio  of  controlled  investments  bringing  total  investment  to  date  to  £12.5  million  to  establish,  develop  and  create  value  in  these  portfolio  companies.    None  of  this  is  shown  on  the  balance  sheet.  Exit  capability  demonstrated  through  the  trade  sale  of  Acolyte  Biomedica  to  3M  Corporation,  returning  an  initial  £0.9  million  and  a  further  earn-out  of  up  to  £4.7  million,  a  multiple  of  up  to  8X  on  ANGLE’s  investment  (see  Note  11).  Six  other  Progeny
®
  companies  progressed  during  the  year,  all  of  which  being  controlled  investments,  have  no  value  on  the  Balance  Sheet.  Operational  progress  towards  exit  made  in  a  number  of  the  underlying  companies,  including  Aberro,  Geomerics,  Novocellus  and  Parsortix,  creating  further  unrealised  value  for  shareholders.
Financial performance
Planned  expenditure  on  controlled  investments  of  £3.1  million    (2006:  £2.2  million)  and  on  ventures  operating  costs  of  £3.0  million    (2006:  £2.5  million).  Adverse  movement  on  quoted  investments  of    £3.0  million  (2006:  gain  of  £2.5  million).  Loss  before  tax  after  this  expenditure  of  £9.3  million  (2006:  £2.7  million).  Cash  balance  at  30  April  2007  of  £2.6  million  (2006:  £8.2  million).  Key developments, post the year end
Full  business  review  completed.  Plan  now  in  place  to  drive  the  business  into  profit  during  the  current  financial  year.
Third  party  investment  into  Progeny
®
  company  Geomerics  resulting  in  a  fair  value  gain  of  £4.0  million  and  a  reduction  in  ongoing  investment  commitments.  Significant  new  long  term  management  contract  awarded  by  the  Innovation  Lincolnshire  Outreach  Programme,  worth  £0.9  million  over  the  next    21  months.  Operating  costs  reduced  by  £2.3  million  on  an  annualised  basis.
Cash  balances  sufficient  to  deliver  revised  plan.
‡
‡
‡
‡
‡
‡
‡
‡
‡
‡
‡
HIGHLIGHTS
